查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1829028

伴侶動物保健市場（按動物類型、產品類型、配方、通路和治療領域）－2025-2032 年全球預測

Companion Animal Health Market by Animal Type, Product Type, Formulation, Distribution Channel, Therapeutic Area - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，伴侶動物保健市場將成長至 1,518.2 億美元，複合年成長率為 18.24%。

主要市場統計數據
基準年2024年 397.2億美元
預計2025年 471.3億美元
預測年份：2032年 1518.2億美元
複合年成長率（%） 18.24%

引人注目的定位，涵蓋伴侶動物健康領域日益成長的需求、不斷變化的相關人員以及策略行動的優先領域

伴侶動物健康領域正經歷一個加速轉型的時代，這得益於飼主期望的改變、科技的進步和照護模式的持續演進。寵物主人越來越將動物視為重要的家庭成員，這推動了對先進診斷、專業營養和新型療法的需求。同時，獸醫診所和通路合作夥伴正在調整其商業模式，重塑其服務和產品的交付方式，以適應遠端醫療、家庭監控和全通路購買行為。

在此背景下，商業性相關人員必須將臨床證據、消費者洞察和供應鏈韌性融入其策略決策中。投資重點正轉向能夠實現遠端監控、提高診斷通量並提供可衡量臨床結果的解決方案，這些方案能夠引起臨床醫生和動物主人的共鳴。此外，監管審查和抗菌藥物管理措施正在影響處方決策和產品開發路徑。這些綜合動態為尋求產品差異化並擴大獸醫院網路和零售通路應用的創新者、製造商和分銷商帶來了挑戰和機會。

展望未來，那些將科學嚴謹性與現實的商業化策略相結合，並預見到分銷和定價壓力變化的領導者將最有可能在這個快速成熟的領域中獲得長期價值。

數位轉型、個人化照護模式和供應鏈彈性如何重塑動物用藥品的產品路徑和競爭優勢

伴侶動物健康生態系統正被幾項趨同的變革重新定義，這些變革正在改變產品開發、臨床實踐和商業性參與。首先，數位化和互聯醫療工具正從試點計劃轉變為醫療服務的核心要素，從而能夠更早發現慢性疾病，並促進獸醫和飼主之間更頻繁的遠距互動。這些工具正在催化新的資料流，以支持結果主導的價值提案和產品差異化。

其次，個人化預防方法日益流行，營養策略和標靶治療可根據生命階段、品種特徵和合併症量身定做。消費者越來越願意投資高階醫療，而臨床醫生也越來越尋求能夠提升生活品質的實證干預措施，進一步強化了這個趨勢。第三，供應鏈敏捷性和採購透明度已成為製造商和經銷商應對不斷變化的原料供應和不斷變化的監管要求的策略要務。這些共同的轉變使得研發、監理和商業團隊之間跨職能協作的重要性日益凸顯。

最後，隨著新參與企業和老牌製造商將其產品組合擴展到診斷、營養、藥品、疫苗等，競爭格局正在加劇。這種轉變的累積效應正在創造一個市場，在這個市場中，臨床信心、數位整合和通路成熟度將決定從利基應用到主流的轉變。

評估累積關稅壓力將如何影響伴侶動物治療、診斷和營養供應鏈中的採購、定價和准入

主要貿易夥伴預期將採取的關稅措施可能會對進口原料、成品或專用設備的伴侶動物保健公司產生累積影響。實際上，關稅上調可能會增加製造商和經銷商的到岸成本，從而擠壓淨利率，除非透過價格調整、資源配置或營運效率的提升來抵消。對於依賴跨境生產注射劑、診斷組件和活性藥物成分的組織而言，關稅的影響可能會增加採購風險，並鼓勵近岸外包或供應商多元化。

除了直接的成本影響外，關稅引發的變化還可能對供應鏈和消費行為間接影響。例如，由於企業優先考慮庫存配置和營運成本保全，進口成本的增加可能導致產品發布延遲或促銷強度減弱。因此，獸醫和寵物飼主可能會發現自己無法獲得某些進口診斷產品和專用營養配方，這促使他們用國產或學名藥進行替代。監管合規和海關監管要求也可能延長前置作業時間，使需求計劃更加複雜，並提高靈活庫存策略的價值。

為了減輕累積關稅的影響，鼓勵相關人員評估基於情境的籌資策略，盡可能重新協商商業條款，並加速產品在地化進程。最終，製造基地的韌性和分銷網路的敏捷性將決定企業如何有效地吸收關稅壓力，同時保持對診所和消費者的服務水準。

將動物類型、產品結構、配方選擇和管道動態與臨床應用和商業機會聯繫起來的深入細分情報

要深入了解市場動態，需要了解多個細分領域的需求和採用模式，以指南產品設計和商業性執行。就動物種類而言，狗仍然專注於預防和慢性病護理創新，而貓則推動著謹慎的家庭治療和專門營養補充劑的採用。就產品類型而言，包括影像、體外診斷和持續監測在內的診斷技術的進步使得更早的發現和更有針對性的治療方案成為可能，而營養創新則強調針對生命週期需求和併發症管理的專門寵物食品配方和補充劑。藥物涵蓋了廣泛的治療方法，包括抗發炎藥物、抗生素、內分泌療法、止痛藥和抗寄生蟲藥，每種藥物都有各自的監管、定價和管理考慮。

劑型選擇－注射劑、口服劑或外用劑－持續影響處方行為和病人順從性。分銷管道的動態變化進一步塑造了獲取和購買模式：線上零售平台擴大了覆蓋範圍並提升了便利性，寵物專賣店在品牌發現方面保持了其重要地位，藥店提供值得信賴的配藥服務，而獸醫診所仍然是專家指導和照護現場產品使用的核心。在循環系統、牙科、皮膚病學、內分泌學、整形外科和寄生蟲學等治療領域，臨床需求與創新管道相互交織，為有針對性的臨床證據生成和商業策略創造了差異化的機會。

總的來說，這些細分強調了綜合產品規劃的重要性，該規劃將配方、管道策略和治療方法定位與臨床工作流程和患者行為相結合，以推動採用並維持價值。

區域動態決定了美洲、歐洲、中東和非洲以及亞太市場的差異化商業化策略

臨床實務、法規環境和消費者偏好的地區差異，形成了獨特的區域動態，從而決定了市場參與企業和現有企業的策略重點。在美洲，成熟的獸醫網路、較高的寵物擁有率以及消費者在預防性和高級護理方面的強勁支出，使得臨床證據成為進入市場和實現差異化的關鍵手段。同時，供應鏈和報銷結構影響著製造商在每個國家和地區市場中如何優先考慮分銷和促銷投資。

在歐洲、中東和非洲，監管協調工作與不同的市場成熟度並存，為區域客製化產品註冊和差異化通路策略創造了機會。在部分地區，本地臨床指南和抗菌藥物管理計畫可能會影響藥物使用模式，促使製造商強調與管理相關的通訊和診斷輔助處方。在全部區域亞太地區，寵物擁有量的快速成長、都市區獸醫基礎設施的不斷擴張以及可支配收入的不斷成長，正在推動對優質營養、先進診斷和便捷治療方案的需求。

綜合起來，這些區域見解表明需要一個靈活的商業化框架，以平衡全球臨床證據產生與特定區域的監管策略、通路夥伴關係以及適應消費行為和醫療保健提供模式差異的行銷方法。

企業的策略重點與競爭措施：結合臨床信譽、供應可靠性和通路成熟度，在動物用藥品取勝

伴侶動物保健領域的競爭優勢日益取決於能否將科學可信度與可擴展的商業性可行性結合。主要企業優先考慮融合診斷、治療和營養解決方案的一體化產品組合，並以結果數據和臨床醫生教育計畫為支持。策略聯盟和選擇性收購是擴展能力組合、獲取獨特技術以及加速進入相關治療和分銷領域的常用方法。

生產和監管事務中的卓越運作仍然至關重要，尤其對於需要嚴格品質系統的注射生技藥品和高級診斷產品。投資於供應鏈視覺性和數位預測工具的組織將在庫存最佳化和服務連續性方面獲得優勢。在商業方面，增強的數位行銷、全通路銷售支援和現場人員培訓將有助於更有效地與獸醫診所和動物飼主互動。此外，更重視上市後證據和真實世界資料收集，可以強化臨床價值提案，並支持與付款人和醫療保健組織進行採購談判。

在這種競爭環境下，敏捷的中型企業可以透過專注於利基治療領域或提供臨床醫生的差異化診斷平台，超越大型現有企業。相反，大型綜​​合企​​業則利用其規模優勢，提供全球供應的連續性和廣泛的分銷管道，與本地專家合作是實現本地化成長的有效途徑。

高階主管可以採取可行的策略行動，以增強證據產生、供應彈性和跨通路商業性差異化

產業領導者應制定多管齊下的行動計劃，以確保臨床信心、最佳化供應鏈並加速商業性應用。首先，優先開發可靠的臨床和現實世界證據，證明患者療效和飼主滿意度顯著改善。其次，重新設計籌資策略，透過供應商多元化、盡可能本地化以及庫存靈活性來降低關稅和物流風險，從而在市場波動期間保持服務水準。

同時，投資支援遠端監控、遠端醫療整合和全通路商務的數位基礎設施，將解鎖新的互動點並提高依從性。開發團隊應針對線上零售商、專賣店、藥局和診所合作夥伴制定針對特定管道的價值提案，確保通訊的一致性和精簡的履約選項。此外，將抗生素管理和法規合規性納入產品策略，以體現臨床責任，同時降低聲譽和監管風險。最後，考慮建立夥伴關係和有針對性的併購，以獲得利基技術和分銷網路，並加快高價值創新產品的上市時間。

實施這些建議將有助於公司建立有彈性的、以證據主導的投資組合，以滿足臨床需求和不斷變化的所有者期望，同時在日益複雜的全球環境中保護利潤和准入。

結合從業者訪談、監管分析和情境規劃的穩健混合方法研究途徑，以檢驗商業性和臨床見解

本調查方法採用混合方法，結合定性和定量證據收集、嚴格的次要研究和專家檢驗。主要研究內容包括與執業獸醫、分銷主管和產品開發負責人進行結構化訪談，以提供有關臨床工作流程、應用障礙和通路經濟性的觀點。二次研究包括監管指南、臨床文獻和行業趨勢分析，以將訪談結果具體化並識別系統性促進因素。

分析方法包括跨細分綜合法，以評估動物類型、產品類型、配方、分銷管道和治療重點如何相互作用，從而影響其應用和商業性成果。此外，還運用情境規劃和敏感度分析來評估外部衝擊（例如關稅調整和供應鏈中斷）的潛在影響。所有研究結果均由專家評審小組進行三角檢驗，以確保解釋的嚴謹性和實際相關性。如果資料變異性或快速變化的監管條件可能影響短期適用性，本研究承認其局限性，並建議透過額外的基礎研究和試點計畫進行有針對性的檢驗。

這種多管齊下的方法確保見解植根於臨床現實、具有商業性可行性並能適應不斷變化的市場條件。

綜合結論：臨床創新、營運韌性與實證商業化是動物保健領域長期成功的支柱

摘要：伴侶動物保健產業正經歷策略整合與創新時期，臨床證據、供應鏈敏捷性和通路成熟度將決定成敗。診斷技術的進步和數位化醫療能力正在改變護理節奏，使早期介入成為可能，並為那些能夠展現出明顯療效的產品和服務創造機會。兼具配方便捷性和療效的營養和藥物產品組合，可望吸引日益成長的業主投資和臨床醫生的偏好。

關稅相關壓力和區域監管差異迫使企業採取積極的採購和打入市場策略，以維持市場准入和利潤率。將強大的循證基礎與適應性製造地和差異化商業模式相結合的企業，將能夠更好地應對市場波動並確保永續成長。最終，通往長期成功的道路將取決於將臨床創新轉化為可擴展的、經實踐檢驗的解決方案，以滿足不斷變化的所有者期望，同時維護管理和安全標準。

現在採取行動調整研發重點、營運能力和打入市場策略的相關人員將有可能在快速成熟的市場中創造永續的競爭優勢。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 越來越多採用遠端醫療平台進行虛擬獸醫諮詢
  • 消費者對特定品種和特定狀況的寵物營養計劃的需求不斷成長
  • 整合穿戴式健康追蹤器，即時監測寵物的生命徵象和活動水平
  • 擴大寵物保險計劃，涵蓋預防保健和專業獸醫護理
  • 犬慢性疾病單株抗體治療進展及商業化
  • 獸醫對基於 CBD 的寵物疼痛管理治療方法的接受度和採用率不斷上升
  • 線上獸醫藥局和直接面對消費者的藥品分銷管道快速成長
  • 開發數位行為健康工具以解決寵物的分離焦慮和壓力
  • 寵物食品對永續成分和環保包裝的需求不斷成長
  • 加強「同一個健康」合作，將寵物疾病監測與人類健康數據整合

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 伴侶動物保健市場（依動物類型）

  • 貓
  • 狗
  • 馬

9. 伴侶動物保健市場（依產品類型）

  • 診斷
    • 影像學
    • 體外診斷
    • 監控設備
  • 營養
    • 特色寵物食品
    • 補充
  • 製藥
    • 抗發炎藥物
    • 抗生素
    • 內分泌治療
    • 疼痛管理
    • 殺寄生蟲劑
  • 疫苗

10. 伴侶動物保健市場（依配方）

  • 注射
  • 口服
  • 外用藥物

11. 伴侶動物保健市場（依通路）

  • 網路零售
  • 寵物專賣店
  • 藥局
  • 獸醫診所

12. 伴侶動物保健市場（依治療領域）

  • 心血管系統
  • 牙科
  • 皮膚科
  • 內分泌
  • 整形外科
  • 寄生蟲學

13. 伴侶動物保健市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 伴侶動物保健市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 伴侶動物保健市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Elanco Animal Health Incorporated
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • IDEXX Laboratories, Inc.
    • Ceva Sante Animale SA
    • Vetoquinol SA
    • Virbac SA
    • Dechra Pharmaceuticals PLC
    • Phibro Animal Health Corporation
Product Code: MRR-4330CC794B35

The Companion Animal Health Market is projected to grow by USD 151.82 billion at a CAGR of 18.24% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 39.72 billion
Estimated Year [2025] USD 47.13 billion
Forecast Year [2032] USD 151.82 billion
CAGR (%) 18.24%

A compelling orientation to the companion animal health sector that frames rising demand drivers, stakeholder shifts, and priority areas for strategic action

The companion animal health landscape is undergoing an era of accelerated transformation driven by shifting owner expectations, technological advances, and evolving care models. Pet guardians increasingly view animals as integral family members, which has elevated demand for advanced diagnostics, specialized nutrition, and novel therapeutics. Concurrently, veterinary practices and channel partners are adapting operating models to accommodate telehealth, at-home monitoring, and omnichannel purchasing behaviors, reshaping how services and products are delivered.

Against this backdrop, commercial stakeholders must integrate clinical evidence, consumer insights, and supply chain resilience into strategic decision-making. Investment priorities are moving toward solutions that enable remote monitoring, improve diagnostic throughput, and deliver measurable clinical outcomes that resonate with both clinicians and owners. Moreover, regulatory scrutiny and antimicrobial stewardship initiatives are influencing formulary decisions and product development pathways. In combination, these dynamics create both challenges and opportunities for innovators, manufacturers, and distributors seeking to differentiate offerings and scale adoption across veterinary networks and retail channels.

Looking ahead, leaders who align scientific rigor with pragmatic commercialization strategies, and who anticipate shifting distribution and pricing pressures, will be best positioned to capture long-term value in this rapidly maturing sector.

How digital transformation, personalized care models, and supply chain resilience are reshaping product pathways and competitive advantage in animal health

The companion animal health ecosystem is being redefined by several convergent shifts that are transforming product development, clinical practice, and commercial engagement. First, digital and connected health tools are moving from pilot projects to core components of care delivery, enabling earlier detection of chronic conditions and more frequent remote interactions between veterinarians and owners. These tools are catalyzing new data streams that support outcome-driven value propositions and product differentiation.

Second, there is a pronounced move toward personalized and preventative approaches, with nutritional strategy and targeted therapeutics increasingly tailored to life stage, breed predispositions, and comorbidities. This trend is reinforced by growing consumer willingness to invest in premium care and by clinicians seeking evidence-based interventions that extend quality of life. Third, supply chain agility and sourcing transparency have become strategic imperatives as manufacturers and distributors respond to fluctuating input availability and evolving regulatory requirements. Together, these shifts elevate the importance of cross-functional collaboration among R&D, regulatory, and commercial teams.

Finally, the competitive landscape is intensifying as new entrants and incumbent manufacturers expand portfolios across diagnostics, nutrition, pharmaceuticals, and vaccines. The cumulative effect of these transformative shifts is a market where clinical credibility, digital integration, and channel sophistication determine who advances from niche adoption to mainstream acceptance.

Assessing how cumulative tariff pressures influence procurement, pricing, and access across companion animal therapeutics, diagnostics, and nutrition supply chains

Projected tariff actions originating from major trading partners can exert a cumulative influence on companion animal health companies that import raw materials, finished goods, or specialized equipment. In practical terms, higher duties increase landed costs for manufacturers and distributors, which can compress margins unless offset through pricing adjustments, re-sourcing, or operational efficiencies. For organizations that rely on cross-border production of injectables, diagnostics components, or pharmaceutical active ingredients, tariff exposure heightens procurement risk and may incentivize nearshoring or supplier diversification.

Beyond direct cost effects, tariff-induced shifts can create secondary impacts across supply chains and consumer behavior. For example, increased import costs may delay product launches or reduce promotional intensity as firms prioritize inventory allocation and working capital preservation. In turn, veterinarians and pet owners may experience constrained access to certain imported diagnostics or specialized nutritional formulations, prompting substitution toward locally produced alternatives or generics. Regulatory compliance and customs administration requirements can also extend lead times, making demand planning more complex and increasing the value of flexible inventory strategies.

To mitigate cumulative tariff impacts, stakeholders are advised to evaluate scenario-based sourcing strategies, renegotiate commercial terms where feasible, and accelerate product localization efforts. Ultimately, the resilience of manufacturing footprints and the agility of distribution networks will determine how effectively companies absorb tariff pressures while maintaining service levels for clinics and consumers.

Deep segmentation intelligence linking animal type, product architecture, formulation choices, and channel dynamics to clinical adoption and commercial opportunity

A granular view of market dynamics requires understanding demand and adoption patterns across multiple segmentation lenses that guide product design and commercial execution. When viewed through animal type, dogs remain a primary focus for preventive and chronic care innovations, while cats drive adoption in discreet, at-home treatments and specialized nutrition; equine markets prioritize performance, reproduction, and pain management solutions with distinct clinical pathways. Considering product type, diagnostic advances spanning imaging, in-vitro diagnostics, and continuous monitoring are enabling earlier detection and more precise treatment selection, whereas nutrition innovation emphasizes specialized pet food formulations and supplements that target lifecycle needs and comorbidity management. Pharmaceuticals encompass a range of modalities from anti-inflammatories and antibiotics to endocrine therapies, analgesics, and parasiticides, each with unique regulatory, pricing, and stewardship considerations.

Formulation choices-injectable, oral, and topical-continually influence prescribing behavior and owner adherence, with injectables favored for clinic-administered interventions, oral formulations supporting at-home chronic disease management, and topicals offering convenience for dermatological and parasitology indications. Distribution channel dynamics further shape access and purchasing patterns; online retail platforms are expanding reach and convenience, pet specialty stores maintain brand discovery roles, pharmacies offer trusted dispensing, and veterinary clinics remain central for professional guidance and point-of-care product use. Therapeutic area focus on cardiovascular, dental, dermatology, endocrine, orthopedic, and parasitology conditions highlights where clinical demand and innovation pipelines intersect, creating differentiated opportunities for targeted clinical evidence generation and tailored commercial strategies.

Taken together, these segmentation perspectives underscore the importance of integrated product planning that aligns formulation, channel strategy, and therapeutic positioning to clinical workflows and owner behaviors in order to accelerate adoption and sustain value.

Regional dynamics that dictate differentiated commercialization playbooks across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Geographic variation in clinical practice, regulatory environments, and consumer preferences creates distinct regional dynamics that shape strategic priorities for market entrants and incumbents alike. In the Americas, established veterinary networks, high pet ownership rates, and strong consumer propensity to spend on preventative and advanced care make market access and clinical evidence the primary levers for differentiation. Meanwhile, supply chain considerations and reimbursement structures influence how manufacturers prioritize distribution and promotional investments across national and subnational markets.

In Europe, Middle East & Africa, regulatory harmonization efforts coexist with diverse market maturity levels, creating opportunities for regionally tailored product registrations and differentiated channel strategies. Local clinical guidelines and antimicrobial stewardship programs in parts of this region can affect pharmaceutical utilization patterns, prompting manufacturers to emphasize stewardship-aligned messaging and diagnostic-enabled prescribing. Across the Asia-Pacific region, rapid pet ownership growth, expanding urban veterinary infrastructures, and rising disposable incomes are accelerating demand for premium nutrition, modern diagnostics, and accessible therapeutic options, while market entry strategies must account for varied regulatory landscapes and local manufacturing incentives.

Collectively, these regional insights point to the need for flexible commercialization frameworks that balance global clinical evidence generation with localized regulatory strategies, channel partnerships, and marketing approaches adapted to differing consumer behaviors and healthcare delivery models.

Strategic corporate priorities and competitive moves that combine clinical credibility, supply reliability, and channel sophistication to win in animal health

Competitive positioning in companion animal health is increasingly determined by the ability to combine scientific credibility with scalable commercial execution. Leading companies are prioritizing integrated portfolios that blend diagnostics, therapeutics, and nutritional solutions, supported by outcome data and clinician education programs. Strategic alliances and selective acquisitions are common approaches to broaden capability sets, access proprietary technologies, and accelerate entry into adjacent therapeutic or distribution segments.

Operational excellence in manufacturing and regulatory affairs remains critical, particularly for injectable biologics and advanced diagnostics that require stringent quality systems. Organizations that invest in supply chain visibility and digital forecasting tools gain advantages in inventory optimization and service continuity. On the commercial front, digital marketing, omnichannel sales enablement, and enhanced field force training support more effective engagement with veterinary practices and pet owners. Moreover, a growing emphasis on post-market evidence and real-world data collection strengthens clinical value propositions and supports payer or institutional procurement discussions.

In this competitive environment, nimble mid-sized firms can outmaneuver larger incumbents by focusing on niche therapeutic areas or by offering differentiated, clinician-facing diagnostic platforms. Conversely, large integrated players leverage scale to deliver global supply continuity and broad distribution, making partnerships with regional specialists an effective route to localized growth.

Actionable strategic moves for executives to strengthen evidence generation, supply resilience, and commercial differentiation across channels

Industry leaders should pursue a multi-pronged action agenda designed to secure clinical trust, optimize supply chains, and accelerate commercial adoption. First, prioritize the generation of robust clinical and real-world evidence that demonstrates measurable improvements in patient outcomes and owner satisfaction; this will strengthen relationships with veterinary opinion leaders and support premium positioning. Next, redesign sourcing strategies to reduce tariff and logistical exposure through supplier diversification, localized production where feasible, and inventory flexibility that preserves service levels during disruptions.

Simultaneously, invest in digital infrastructure that supports remote monitoring, telehealth integration, and omnichannel commerce, thereby capturing new engagement points and improving adherence. Commercial teams should develop channel-specific value propositions tailored to online retailers, specialty stores, pharmacies, and clinic partners, ensuring consistent messaging and streamlined fulfillment options. Additionally, embed antimicrobial stewardship and regulatory compliance into product strategies to mitigate reputational and regulatory risk while demonstrating clinical responsibility. Finally, explore partnerships and targeted M&A to acquire niche technologies or distribution reach, accelerating time to market for high-value innovations.

By implementing these recommendations, organizations can build resilient, evidence-driven portfolios that address clinical needs and changing owner expectations while safeguarding margin and access in an increasingly complex global environment.

Robust mixed-method research approach combining practitioner interviews, regulatory analysis, and scenario planning to validate commercial and clinical insights

The research underpinning this analysis draws on a blended methodology combining qualitative and quantitative evidence collection, rigorous secondary research, and expert validation. Primary inputs included structured interviews with practicing veterinarians, distribution executives, and product development leaders, providing perspective on clinical workflows, adoption barriers, and channel economics. Secondary research encompassed regulatory guidance, clinical literature, and industry trend analyses to contextualize interview findings and identify systemic drivers.

Analytical methods included cross-segmentation synthesis to evaluate how animal type, product typology, formulation, distribution channel, and therapeutic focus interact to influence adoption and commercial outcomes. Scenario planning and sensitivity analysis were applied to assess potential impacts of external shocks such as tariff adjustments and supply chain disruptions. All findings were triangulated with expert review panels to ensure interpretive rigor and practical relevance. Limitations of the study are acknowledged where data variability or rapidly evolving regulatory conditions may affect near-term applicability, and recommendations are provided with pathways for targeted validation through additional primary research or pilot programs.

This multi-method approach ensures the insights are grounded in clinical reality, commercially actionable, and adaptable to evolving market conditions.

Concluding synthesis that links clinical innovation, operational resilience, and evidence-driven commercialization as the pillars of long-term success in animal health

In summary, companion animal health is entering a period of strategic consolidation and innovation where clinical evidence, supply chain agility, and channel sophistication will determine winners. Diagnostic advancements and digital health capabilities are changing the tempo of care, enabling earlier intervention and creating opportunities for products and services that demonstrate clear outcome benefits. Nutrition and pharmaceutical portfolios that align formulation convenience with therapeutic effectiveness will capture increasing owner investment and clinician preference.

Tariff-related pressures and regional regulatory variation require proactive sourcing and market entry strategies to preserve access and margin. Companies that integrate robust evidence generation with adaptive manufacturing footprints and differentiated commercial models will be better positioned to navigate volatility and secure sustainable growth. Ultimately, the path to long-term success relies on translating clinical innovation into scalable, practitioner-validated solutions that meet evolving owner expectations while upholding standards of stewardship and safety.

Stakeholders who act now to align R&D priorities, operational capabilities, and market access strategies will create durable competitive advantage in a rapidly maturing market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of telehealth platforms for virtual veterinary consultations
  • 5.2. Rising consumer demand for breed-specific and condition-targeted pet nutrition plans
  • 5.3. Integration of wearable health trackers for real-time monitoring of pet vital signs and activity levels
  • 5.4. Expansion of pet insurance plans covering preventive care and specialized veterinary treatments
  • 5.5. Advancement and commercialization of monoclonal antibody therapies for chronic canine diseases
  • 5.6. Surge in veterinary acceptance and adoption of CBD-based therapies for pet pain management
  • 5.7. Rapid growth of online veterinary pharmacies and direct-to-consumer medication distribution channels
  • 5.8. Development of digital behavioral health tools addressing separation anxiety and stress in pets
  • 5.9. Emerging demand for sustainably sourced ingredients and eco-friendly packaging in pet food products
  • 5.10. Strengthening One Health collaborations to integrate pet disease surveillance with human health data

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Companion Animal Health Market, by Animal Type

  • 8.1. Cat
  • 8.2. Dog
  • 8.3. Horse

9. Companion Animal Health Market, by Product Type

  • 9.1. Diagnostics
    • 9.1.1. Imaging
    • 9.1.2. In Vitro Diagnostics
    • 9.1.3. Monitoring Devices
  • 9.2. Nutrition
    • 9.2.1. Specialized Pet Food
    • 9.2.2. Supplements
  • 9.3. Pharmaceuticals
    • 9.3.1. Anti-Inflammatories
    • 9.3.2. Antibiotics
    • 9.3.3. Endocrine Treatments
    • 9.3.4. Pain Management
    • 9.3.5. Parasiticides
  • 9.4. Vaccines

10. Companion Animal Health Market, by Formulation

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Topical

11. Companion Animal Health Market, by Distribution Channel

  • 11.1. Online Retail
  • 11.2. Pet Specialty Stores
  • 11.3. Pharmacies
  • 11.4. Veterinary Clinics

12. Companion Animal Health Market, by Therapeutic Area

  • 12.1. Cardiovascular
  • 12.2. Dental
  • 12.3. Dermatology
  • 12.4. Endocrine
  • 12.5. Orthopedic
  • 12.6. Parasitology

13. Companion Animal Health Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Companion Animal Health Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Companion Animal Health Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Elanco Animal Health Incorporated
    • 16.3.2. Zoetis Inc.
    • 16.3.3. Merck & Co., Inc.
    • 16.3.4. Boehringer Ingelheim International GmbH
    • 16.3.5. IDEXX Laboratories, Inc.
    • 16.3.6. Ceva Sante Animale S.A.
    • 16.3.7. Vetoquinol S.A.
    • 16.3.8. Virbac S.A.
    • 16.3.9. Dechra Pharmaceuticals PLC
    • 16.3.10. Phibro Animal Health Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. COMPANION ANIMAL HEALTH MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. COMPANION ANIMAL HEALTH MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COMPANION ANIMAL HEALTH MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018